Table 1

Results of the economic evaluation

Total QALYs (95% CI)†Mean (95% CI) drug cost†Mean (95% CI) administration and monitoring costMean (95% CI) medication/medical service cost†Total cost (95% CI)†Total net benefits (95% CI)†‡
Discontinuous bevacizumab1.584 (1.538 to 1.630)£651 (£605 to £698)£1825 (£1708 to £1941)£526 (£144 to £908)£3002 (£2601 to £3403)£28 683 (£27 707 to £29 658)
Continuous bevacizumab1.604 (1.563 to 1.645)£1065 (£1048 to £1081)£1952 (£1860 to £2043)£585 (£250 to £919)£3601 (£3259 to £3943)£28 480 (£27 548 to £29 412)
Discontinuous ranibizumab1.582 (1.530 to 1.634)£9229 (£8584 to £9875)£1838 (£1724 to £1952)£432 (£253 to £611)£11 500 (£10 798 to £12 202)£20 142 (£18 963 to £21 321)
Continuous ranibizumab1.608 (1.565 to 1.651)£16 286 (£16 011 to £16 562)£1970 (£1883 to £2057)£334 (£215 to £452)£18 590 (£18 258 to £18 922)£13 576 (£12 769 to £14 383)
Difference: ranibizumab vs bevacizumabContinuous: 0.004 (−0.046 to 0.054)Continuous: £15 222 (£14 948 to £15 495)*£16 (−£109 to £141)Continuous: −£251 (−£604 to £102)Continuous: £14 989 (£14 522 to £15 456)*Continuous: −£14 904 (−£15 995 to −£13 813)*
Discontinuous: −0.002 (−0.064 to 0.060)Discontinuous: £8578 (£7932 to £9225)*Discontinuous: −£94 (−£514 to £326)Discontinuous: £8498 (£7700 to £9295)*Discontinuous: −£8541 (−£9939 to −£7144)*
Difference: continuous vs discontinuousRanibizumab: 0.026 (−0.032 to 0.085)Ranibizumab: £7057 (£6364 to £7750)*£130 (£20 to £239)*Ranibizumab: −£98 (−£310 to £113)Ranibizumab: £7090 (£6337 to £7844)*Ranibizumab: −£6566 (−£7861 to −£5271)*
Bevacizumab: 0.020 (−0.032 to 0.071)Bevacizumab: £413 (£365 to £462)*Bevacizumab: £59 (−£438 to £556)Bevacizumab: £599 (£91 to £1107)*Bevacizumab: −£203 (−£1372 to £967)
Interaction0.006 (−0.071 to 0.084)£6643 (£5949 to £7338)*£5 (−£31 to £42)−£157 (−£696 to £381)£6491 (£5604 to £7379)*−£6363 (−£8088 to −£4638)*
  • *Significantly different from zero (p<0.05).

  • †Analysis allowed for interactions.

  • ‡Net benefits equal QALYs multiplied by ceiling ratio minus costs; the net benefits shown in this table were calculated at a £20 000/QALY ceiling ratio.